Novavax Announces Closing of Public Offering
16 Abril 2018 - 5:05PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company
committed to delivering novel products to prevent infectious
diseases, today announced the closing of the underwritten public
offering priced on Wednesday, April 11, 2018.
The company issued 34,848,507 shares of its
common stock, including 4,545,457 shares pursuant to the
underwriters’ option to purchase additional shares. The shares were
issued at $1.65 per share resulting in total gross proceeds from
this offering of $57.5 million before deducting the underwriters
discount and offering expenses.
Net proceeds from the offering are to be used
for general corporate purposes, including but not limited to
working capital, capital expenditures, research and development
expenditures related to clinical and preclinical vaccine
candidates, clinical trial expenditures, as well as acquisitions
and other strategic purposes.
Citigroup and Piper Jaffray & Co. acted as
joint book-running managers of the offering. Cantor Fitzgerald
& Co. also acted as a book-running manager. Ladenburg Thalmann
and B. Riley FBR acted as co-managers.
The shares described above were issued pursuant
to a final prospectus supplement and accompanying prospectus. The
company filed the final prospectus supplement relating to the
offering with the Securities and Exchange Commission (“SEC”) on
April 13, 2018, which is available along with the accompanying
prospectus filed with the SEC in connection with the company’s
shelf registration statement on Form S-3, previously declared
effective by the SEC, on the SEC’s website at www.sec.gov. This
press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy, nor will there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Copies of the final prospectus supplement and the
accompanying prospectus may be obtained from Citigroup and Piper
Jaffray & Co., Attention: Citigroup, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (800) 831-9146; or Piper Jaffray & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone at (800) 747-3924 or by email at
prospectus@pjc.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biotechnology company committed to delivering novel products to
prevent infectious diseases. Its RSV and influenza
nanoparticle vaccine candidates are Novavax’ most advanced
clinical programs and are at the forefront of Novavax’ efforts to
improve global health.
Forward-Looking Statements
Statements contained in this release using words
such as "expects" and "intends" are forward-looking statements that
involve a number of risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements. These risks and uncertainties include, but are not
limited to: the possible adverse impact on the market price of our
shares of common stock due to the dilutive effect of the securities
sold in the offering; our planned use of the proceeds from this
offering; capital market risks; our ability to raise additional
capital when needed; and other risk factors identified from time to
time in the reports we file with the SEC, including our Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current
Reports on Form 8-K, which are available at www.sec.gov. We caution
investors not to place considerable reliance on the forward-looking
statements contained in this press release. You are encouraged to
read our filings with the SEC, available at sec.gov, for a
discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this document, and we undertake no obligation to update
or revise any of the statements. Our business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors and others should give
careful consideration to these risks and uncertainties.
Contact:
Investors:Erika TrahanSenior Manager, Investor & Public
Relationsir@novavax.com240-268-2000
Westwicke PartnersJohn
WoolfordJohn.woolford@westwicke.com443-213-0506
Media:Sam BrownMike Beyermikebeyer@sambrown.com312-961-2502
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024